Posted by Michael Wonder on 12 Dec 2018
The Menarini Group announces meropenem/vaborbactam European marketing authorisation
11 December 2018 - The first combination of a carbapenem and a beta-lactamase inhibitor approved for clinical use in Europe.
Meropenem/vaborbactam approved on 20 November 2018 by the European Commission for clinical use in adult patients with difficult-to-treat infections.
The Menarini Group has recently reached an agreement with Melinta Therapeutics to commercialise meropenem/vaborbactam in Europe, Asia-Pacific and CIS.
The European approval relied also on the results of the TANGO II trial, the largest trial conducted so far in patients with carbapenem-resistant Enterobacteriaceae infections.
